EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Left Ventricular Thrombus in Oncology Patients and Beyond: Imaging, Treatment Choices, and Duration

Ameer Awashra iD, Ahmed Emara iD, Mohammed AbuBaha, Bayan Mahafdah, Kareem Istetieh, Bara AbuBaha, Samia Aldwaik, Tujan Hamed, Mariam Assi, Hamza A Abdul-Hafez iD, Abdullah Faisal Albukhari, Mohamed S Elgendy und 1 weitere

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261437022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 26.03.2026. Verfasst von Ameer Awashra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, An-Najah National University, Nablus, Palestine. Hauptthemen laut MEDLINE: Thrombosis, Neoplasms, Heart Ventricles, Heart Diseases. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Left ventricular thrombus (LVT) is a significant complication linked to myocardial infarction and marked left ventricular dysfunction. its detection has increased among oncology patients; this may be attributed to the cardiotoxic effects of cancer therapies. The prothrombotic state occur in cancer which is caused by factors include hypercoagulability, persistent systemic inflammation, and endothelial injury promote an environment conducive to thrombus formation.

Methods

A comprehensive review was conducted through PubMed, Scopus, and leading cardiology and oncology society guidelines up to October 2025. Relevant studies were analyzed to provide an overview of the epidemiology, mechanisms, diagnostic imaging approaches, treatment strategies, and prognosis of left ventricular thrombus in both oncology and non-oncology populations.

Results

LVT occurred in approximately 4%–15% of patients after myocardial infarction, with an increased incidence among those with chemotherapy-induced cardiomyopathy. Transthoracic echocardiography (TTE) is the initial diagnostic test, while cardiac magnetic resonance imaging (CMR) with late gadolinium enhancement is the gold standard. Anticoagulation with either vitamin K antagonists or direct oral anticoagulants (DOACs) effectively reduces embolic risk. Oncology patients pose additional concerns, because they had increased bleeding risk and potential drug interactions. Currently, both American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines lack cancer-specific recommendations.

Conclusion

LVT in oncology patients results from a combination of factors, including cancer-related thrombosis and therapy-induced cardiac dysfunction factors. Early detection and individualized anticoagulation are important. More specific studies are urgently required to establish optimal therapy duration, cancer-specific cardio-oncology guidelines to enhance safety and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombosisNeoplasmsHeart VentriclesHeart DiseasesVentricular Dysfunction, LeftHumans

Stichwörter der Autor:innen

anticoagulation therapycancer associated thrombosiscardiac magnetic resonancecardio-oncologydirect oral anticoagulants (DOACs)left ventricular thrombus

Autor:innen und Institutionen

  • Department of Medicine, An-Najah National University, Nablus, Palestine.
  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Faculty of Medicine, Yarmouk University, Irbid, Jordan.
  • Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
  • Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
  • Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.

ORCID-Profile: Ameer Awashra, Ahmed Emara, Hamza A Abdul-Hafez

Zitieren

APA

Awashra, A., Emara, A., AbuBaha, M., Mahafdah, B., Istetieh, K., AbuBaha, B., Aldwaik, S., Hamed, T., Assi, M., Abdul-Hafez, H. A., Faisal Albukhari, A., Elgendy, M. S., & Shubietah, A. (2026). Left Ventricular Thrombus in Oncology Patients and Beyond: Imaging, Treatment Choices, and Duration. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261437022

Vancouver

Awashra A, Emara A, AbuBaha M, Mahafdah B, Istetieh K, AbuBaha B, et al. Left Ventricular Thrombus in Oncology Patients and Beyond: Imaging, Treatment Choices, and Duration. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261437022

BibTeX
@article{Awashra2026,
  author = {Awashra, Ameer and Emara, Ahmed and AbuBaha, Mohammed and Mahafdah, Bayan and Istetieh, Kareem and AbuBaha, Bara and Aldwaik, Samia and Hamed, Tujan and Assi, Mariam and Abdul-Hafez, Hamza A and Faisal Albukhari, Abdullah and Elgendy, Mohamed S and Shubietah, Abdalhakim},
  title = {Left Ventricular Thrombus in Oncology Patients and Beyond: Imaging, Treatment Choices, and Duration},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261437022}
}
Kostenlos starten →